Clinical Trials Logo

Filter by:
NCT ID: NCT05085626 Recruiting - HRD+Breast Cancer Clinical Trials

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Start date: February 8, 2021
Phase: Phase 2
Study type: Interventional

This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.

NCT ID: NCT05085444 Recruiting - Autoimmune Diseases Clinical Trials

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Start date: October 8, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

NCT ID: NCT05085431 Recruiting - Autoimmune Diseases Clinical Trials

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Start date: November 5, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

NCT ID: NCT05085418 Recruiting - Autoimmune Diseases Clinical Trials

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Start date: November 5, 2021
Phase: Early Phase 1
Study type: Interventional

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

NCT ID: NCT05085145 Recruiting - COVID-19 Clinical Trials

Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV

Start date: September 1, 2021
Phase: Phase 4
Study type: Interventional

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused pandemic since outbreak in 2020. Patients with HIV may be at higher risk than those without HIV for coronavirus disease 2019 (COVID-19). At present, limited data are available on the safety and immunogenicity of coronavirus vaccine for patients with HIV.

NCT ID: NCT05085106 Recruiting - Healthy Clinical Trials

Safety, Tolerability and Pharmacokinetics of Felbinac Trometamol Eye Drops

Binaprofen
Start date: October 21, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of felbinac trometamol eye drops of single-dose, multiple-dose, dose escalation in healthy subjects, for providing the basis for the dose setting in the later clinical study.

NCT ID: NCT05085067 Recruiting - Clinical trials for Retained Products of Conception

The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Retained product of conception (RPOC) is defined by abnormal trophoblastic persistence or retained placenta inside the uterus cavity after a pregnancy independently of the outcome. Untreated RPOC can compromise future fertility. RPOC are generally treated surgically, either by repeated evacuation or by hysteroscopy, which exposes the uterus to additional potential trauma.The combination of trauma to the gravid uterine cavity, hypoestrogenic state at the time of the operation or immediately afterward and local infection is considered to be the pathogenic mechanism of intrauterine adhesions (IUA) , manifested clinically by menstrual abnormalities, infertility and recurrent pregnancy loss.To investigate the efficacy of auto-cross linked hyaluronic acid gel in the prevention of adhesion reformation after hysteroscopic resection of retained products of conception. After the completion of hysteroscopic resection of retained products of conception, patients will be randomized to one of the two groups by computer-generated numbers: [1] infusing auto-cross linked hyaluronic acid gel into intrauterine cavity in the experimental group; [2] no auto-cross linked hyaluronic acid gel into intrauterine cavity in the control group. Second and third look outpatient hysteroscopy will be performed 4 and 8 weeks after the initial surgery. The patients will be followed up about menstrual pattern at 3 months after the surgery.The patients will be followed up about pregancy outcome at 12 months after the surgery.

NCT ID: NCT05084677 Recruiting - Cervical Cancer Clinical Trials

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

To explore the efficacy and tolerance of adding toripalimab simultaneously and subsequently to concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical cancer.

NCT ID: NCT05084365 Recruiting - Parkinson Disease Clinical Trials

A 6-month Study to Evaluate Sulforaphane Effects in PD Patients

Start date: November 28, 2021
Phase: Phase 2
Study type: Interventional

Parkinson's disease (PD) is a second common neurodegenerative disease. More than 6 million individuals worldwide have Parkinson disease. No disease-modifying pharmacologic treatments are available. Current medical treatment is symptomatic, focused on improvement in motor (eg, tremor, rigidity, bradykinesia) and nonmotor (eg, constipation, cognition, mood, sleep) signs and symptoms. Accumulating evidence suggests the important role for inflammation and oxidative stress in the pathogenesis of PD. Sulforaphane extracted from broccoli sprout is an agent with potent anti-oxidant and anti-inflammatory activity. Previous studies suggested sulforaphane is useful in dopaminergic neuron survival. In this study, the investigator attempts to evaluate the efficacy and safety of sulforaphane in PD patients.

NCT ID: NCT05084079 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT

Start date: November 2021
Phase: Phase 4
Study type: Interventional

To compare the effects of different initial insulin dose regimens during the short-term insulin intensive treatment on time to glycemic goal, hypoglycemia prevalence, glycemic variability and other safety problems in newly diagnosed type 2 diabetes mellitus(T2DM) patients, in order to investigate the rational of formula based initiation regimen.